Melanoma of Unknown Primary
Associated Genetic Biomarkers
There are 9 clinical trials for melanoma of unknown primary, of which 7 are open and 2 are completed or closed. Of the trials that contain melanoma of unknown primary as an inclusion criterion, 1 is phase 1 (1 open) and 8 are phase 2 (6 open).
BRAF is the most frequent gene inclusion criterion for melanoma of unknown primary clinical trials .
Binimetinib, encorafenib, and nivolumab are the most common interventions in melanoma of unknown primary clinical trials.
Significant Genes in Melanoma of Unknown Primary
BRAF is an inclusion eligibility criterion in 4 clinical trials for melanoma of unknown primary, of which 2 are open and 2 are closed. Of the trials that contain BRAF status and melanoma of unknown primary as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.